Sysmex Corporation (TYO:6869)
Japan · Delayed Price · Currency is JPY | Market Cap | 830.66B -48.5% |
| Revenue (ttm) | 502.95B +0.2% |
| Net Income | 44.75B -22.6% |
| EPS | 71.77 -22.5% |
| Shares Out | 615.31M |
| PE Ratio | 18.81 |
| Forward PE | 18.79 |
| Dividend | 36.00 (2.73%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 4,949,600 |
| Average Volume | 3,586,065 |
| Open | 1,350.00 |
| Previous Close | 1,319.00 |
| Day's Range | 1,333.50 - 1,359.00 |
| 52-Week Range | 1,268.00 - 2,710.50 |
| Beta | 0.65 |
| RSI | 41.82 |
| Earnings Date | May 14, 2026 |
About Sysmex
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co... [Read more]
Financial Performance
In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.
Financial StatementsNews
Sysmex upgraded to Buy from Hold at Jefferies
Jefferies analyst Stephen Barker upgraded Sysmex to Buy from Hold with a price target of 3,100 yen, up from 2,700 yen. The company’s China outlook stabilizing and India is “taking